EGQ0 Stock Chart & Stats
€0.21
-€0.02(-5.23%)
At close: 4:00 PM EST
€0.21
-€0.02(-5.23%)
Day’s Range― - ―
52-Week Range€0.08 - €0.31
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€15.24M
Enterprise Value€67.66
Total Cash (Recent Filing)€13.80M
Total Debt (Recent Filing)€270.31K
Price to Earnings (P/E)―
Beta-0.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding140,775,450
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.46
Price to Sales (P/S)22.67
P/FCF Ratio-8.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits interest and refinancing pressure, preserving financial flexibility while INOVIQ funds product development and seeks commercial traction. This provides a stronger solvency base than a similarly loss-making business carrying substantial debt.
Platform OptionalityINOVIQ’s biomarker platform can serve clinical, research and industry customers, while partnerships may broaden distribution and applications. Multiple commercialisation routes create longer-term optionality beyond dependence on a single diagnostic product.
Improving Burn TrendAlthough cash generation remains negative, an improved free-cash-flow burn rate versus the prior year indicates some progress in controlling investment-related outflows. Sustained improvement could extend funding runway and reduce reliance on external capital.
Bears Say
Revenue ContractionThe sharp revenue decline shows that commercial scale and demand remain fragile. A smaller revenue base makes fixed research, development and corporate costs harder to absorb, limiting operating leverage and weakening confidence in near-term business durability.
Persistent LossesINOVIQ has not yet demonstrated a cost base supported by revenue. Continued large losses consume equity and require ongoing funding, while the latest period provides no clear evidence that commercial growth is approaching sustainable operating profitability.
Ongoing Cash BurnPersistent negative operating cash flow means the business is funding operations and investment from its balance sheet rather than internally generated cash. The latest deterioration increases dependence on cash reserves or future financing to sustain development.
Inoviq Ltd News
EGQ0 FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest stock price was €0.08 and its highest was €0.31 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is €15.24M.
When is Inoviq Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inoviq Ltd’s earnings last quarter?
Currently, no data Available
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in DE:EGQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:EGQ0 Sentiment 92%
Sector Average 60%
Sector Average 60%
Insider Transactions
Bought Shares
Worth €8.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.77%
Trailing 12-Months
Company Description
Inoviq Ltd
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Technical Analysis
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Imagion Biosystems Ltd.
―